Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) issued its earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06), Zacks reports. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the company posted ($0.39) EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year.

Recursion Pharmaceuticals Trading Down 0.2 %

NASDAQ:RXRX traded down $0.01 on Friday, hitting $4.38. 12,703,872 shares of the stock were exchanged, compared to its average volume of 12,870,430. The company's 50-day moving average price is $5.57 and its 200 day moving average price is $6.68. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -2.86 and a beta of 0.99. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A hedge fund recently raised its stake in Recursion Pharmaceuticals stock. Brighton Jones LLC increased its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 49.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,261 shares of the company's stock after acquiring an additional 6,699 shares during the period. Brighton Jones LLC's holdings in Recursion Pharmaceuticals were worth $137,000 as of its most recent filing with the SEC. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of recent research reports. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC lowered their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.